February 2:
Speakers at Swecare's Programme at Expo Dubai 

1-2 February 2022

February 1: Speakers LINK

February 2: Introductory Keynote Speakers

Lena Hallengren

Minister for Health and Social Affairs
Digital participation

 

Hans Hägglund is specialist in hematology, professor at Uppsala University, the National Cancer Coordinator and chairman of the Confederation of Regional Cancer Centres.He served 5 years as Director of the Uppsala Cancer Center, former President of the Swedish Society of Hematology, affiliated researcher in Entrepreneurship, Innovation and Technology, Stockholm School of Economics and the co-founder & chairman of Vision Zero Cancer.
Hans Hägglund

Professor, National Cancer Coordinator, chair of the Confederation of Regional Cancer Centres, co-founder and chair of Vision Zero Cancer, Sweden
 

Speakers and Panelists

Cristian Massacesi, M.D. is a trained medical oncologist with 20+ years of drug development experience at the world’s top pharmaceutical companies. Oncology Chief Development Officer, he leads AstraZeneca’s late-stage Oncology portfolio of 13 innovative medicines and immunotherapies and oversees ~150 clinical studies focused in core disease areas: breast, lung, gastrointestinal, genitourinary, and gynecological cancers.
Cristian Massacesi

Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca

Digital participation
 

Roberto Verganti is Professor of Leadership and Innovation at the Stockholm School of Economics and on the Faculty of the Harvard Business School. Roberto serves on the Advisory Board of the European Innovation Council. Professor Verganti has authored several books and +150 articles on innovation, management and leadership and has served as advisor to executives, senior managers, national and regional governments on innovation.
Roberto Verganti

Professor of Leadership and Innovation, Stockholm School of Economics, Advisory Board of the European Innovation Council at the European Commission
Digital participation

Anna Martling is a Professor of Surgery and chief physician at Tema Cancer; coordinating chairman of the Task force for implementing Precision Medicine in Region Stockholm and Dean at Karolinska Institutet North.She heads the research group on colorectal surgery. In 2021 she was awarded the prize “Cancer Researcher of the Year”. She is considered a world leading expert in her field and is a frequent lecturer in Sweden and abroad.
Anna Martling

Professor of Surgery at Karolinska Institutet, Senior Consultant Colorectal Surgeon at Karolinska University Hospital
 

Bettina Ryll holds MBBS and PhD in Biomedical Sciences-Molecular Biology, with interest in the interface of Molecular Biology and Medicine. She is also engaged in Melanoma Patient Advocacy, as founder of the Melanoma Patient Network Europe, a mission-driven patient network. Dr. Ryll is a Member of the first EU Cancer Mission board and currently working with Zero Vision Cancer, the Swedish Cancer Mission.
Bettina Ryll

MD, PhD, Personalised Medicine and Patient-centric Innovation at Vision Zero Cancer, Founder Melanoma Patient Network Europe

Itedale Namro Redwan holds a PhD degree in Chemistry with emphasis on Medicinal/Organic Chemistry from the University of Gothenburg and Postdoctoral training in Chemical Biology at the Gladstone Institutes in San Francisco. She was an Assistant Professor at the University of Gothenburg prior to joining CELLINK. Today, Itedale is the Chief Scientific Officer, leading the Science and Applications team in the R&D department.
Itedale Namro Redwan

Chief Scientific Officer, Cellink

 

Professor Vesa Kataja is a clinical oncologist, with +30 years' of experience in oncology, as radiotherapy department head, Chief Physician of Oncology and Hospital Chief Medical Director. Prostate and breast cancer patients are main interests, from screening, treatment and long-term follow-up. Kataja is a lecturer, public presenter, opinion leader and advisor to the Government of Finland. Professor Kataja’s has published > 200 peer-reviewed publications.
Vesa Kataja

Chief Medical Officer, Kaiku Health – a part of Elekta

 

Beatrice Melin, an experienced Medical Doctor and a professor in oncology at Umeå university, is also Director of Research Development and Innovation at Region Västerbotten.Skilled in Clinical Research, Life Sciences, Genetics, Cancer, she is a senior consultant (attending) physician at Department of Radiation Sciences at Umeå University Hospital. She is head project leader of PREDICT case cohort.

 
Beatrice Melin

Professor in Oncology, Umeå University, Director of Research Development and Innovation, Region Västerbotten, Sweden
Digital participation

As a researcher, Sophia Zackrisson is responsible for research and radiology education and a research group leader, Lund University breast Cancer Imaging group, LUCI. Since 2021 she serves as the Director of Lund University Cancer Centre, a strategic research area at Lund University, supporting both the university and Skåne University Hospital managements in strategic decisions in the cancer field.
Sophia Zackrisson

Professor of Radiology at Lund University and Senior Consultant Radiologist at Skåne University Hospital
Digital participation

Henrik Grönberg is Professor in Cancer Epidemiology and chief physician. He was awarded the Cancer Researcher of the Year award in 2022. His world-leading research has contributed to the early and accurate detection of prostate cancer. The research has led to the development of the Stockholm3 blood test, combining protein and genetic markers and clinical data to early detect prostate cancer that requires treatment.
Henrik Grönberg

Professor in Cancer Epidemiology, Karolinska Institutet, Sweden

Digital participation

David CL Lam, MD, is a Clinical Associate Professor, Honorary Consultant, Department of Medicine, Queen Mary Hospital, Hong Kong, Honorary Consultant, Department of Medicine, HKU-Shenzhen Hospital, IASLC Screening and Early Detection committee
David CL Lam

Clinical Associate Professor, Honorary Consultant, at Queen Mary Hospital, Hong Kong, and HKU-Shenzhen Hospital
Digital participation

Dr Humaid Al-Shamsi has expertise in solid tumors and aspecial interest and training in Gastrointestinal Oncology & Palliative oncology. President of the Emirates Oncology Society and Adjunct Clinical Professor of Oncology at the University of Sharjah, he pioneers the UAE Oncology field.
He has served as an Advisor and Member of Governmental committees at the Dept of Health Abud Dhabi, Dubai health authorities, and MoH.
Humaid Al Shamsi

Founder and Director of the Medical Oncology Service at Burjeel Medical City - VPS healthcare
 

Dr. Asma Al Mannaei with +15 years in the Department of Health, leading the transformation in patient care quality and safety; contributing to building an advanced patient-centred healthcare system. She holds a Master’s degrees in Public Health from Johns Hopkins University and a Bachelor’s degree in Medicine from UAEU.One focus is on assessing the adoption of new innovations.
 
Asma Al Mannaei

MD, Executive Director, Research and Innovation Centre at the Department of Health

Executive Director of the Community Health Division at the AD Public Health Center, specialist in the field of public health and leadership, practicing consultant physician in the field of diabetes, endocrinology and metabolic diseases, Dr. Omniyat studied medicine, worked and trained in Ireland for 12 years and worked around twenty years at several Abu Dhabi Hospitals. Dr. Omniyat also worked at the first Health Authority established in Abu Dhabi.
H.E. Omniyat Al Hajeri

Executive Director of Community Health Sector, Abu Dhabi Public Health Center

Björn Zoëga, MD, PhD has for the past 20 years held leading positions within the healthcare sector in Iceland, Sweden and in the USA; as CEO of Landspitali University Hospital and the COO of NextCODE Health. Prior to joining Karolinska University Hospital Björn Zoëga was CMO at Global Health Partner. 
Björn Zoëga

CEO, Karolinska University Hospital

 

Dr. Andrea Ballagi has a MD degree from Budapest, PhD studies at the Ludwig Institute of Cancer Research, Uppsala and an MBA degree from the Uppsala University, Sweden. She has held various positions at IDEXX Laboratories, before joining Olink in 2012. Dr. Ballagi has a thorough understanding of science and how to build competitive teams to successfully commercialize biotechnological products.
Dr. Andrea Ballagi

Vice President, Sales & Marketing, EMEA Olink Proteomics AB

Richard Rosenquist Brandell is the director of Genomic Medicine Sweden, a national infrastructure for implementation of precision medicine. With a background from Umeå University, he became Professor at Uppsala University. Since 2017, he is Senior Physician and Professor at Karolinska University Hospital, focusing on hematological malignancies and sequencing technologies, and a member of the Nobel Assembly, Karolinska Institute.
 
Richard Rosenquist Brandell

Professor Clinical Genetics, Karolinska Institutet; Senior Consultant, Karolinska University Hospital; Chair, Genomic Medicine Sweden
 

Wilfred Ngwa is Professor of Radiation Oncology, and Public Health, Director of the Comprehensive Cancer Center in the Cloud, and dedicated to catalyzing collaborations to increase access to cancer care. Dr Ngwa has held professorships at Harvard, the University of Massachusetts and Tufts University, and has published many works on e.g. global radiation oncology. He currently chairs a Lancet Oncology Commission..

Dr Ngwa is widely recognized for his strong commitment as a leader to catalyze high impact collaborations between high income and low/middle income countries to advance global oncology, working with individuals, institutions, the diaspora, industry and government to ensure sustainability and impact.  Dr Ngwa has won numerous awards including over 18 prestigious awards/honors over the past 6 years alone from Harvard, the United States National Institutes of Health, the American Association of Physicists in Medicine, and international professional societies and organizations for his leading efforts in global health and radiation oncology. 
Wilfred Ngwa

Associate Professor of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine
Digital participation

Associate Prof. Dr. Bora Tas has +10 years clinical experience managing the Physics and Dosimetry for a high-volume Radiation Oncology Department. Skilled in X-Ray, Electrons, MRI, Medical Devices, Dosimetry, and Oncology Management, dr. Tas leads the MR-Linac and Linac Business Lines in Region TIMEA, Elekta. Further, Bora Tas is a strong academic professional with PhD in Medical Physics, editorial board member and reviewer of scientific journals.
Bora Tas

Director MR Linac Region Turkey, India, Middle East and Africa at Elekta
 

Before her present position, Frida Lundmark  was responsible for the development of Vinnova's national investment in precision medicine, the area of antibiotic resistance and Vinnova's strategic support for Life Science and research infrastructures. Prior to that, she was assignment manager for Stockholm County Council's medical biobank, where she was responsible for the development of strategies for large-scale biobanking.
Frida Lundmark

Policy Expert, the Swedish Association of the Pharmaceutical Industry

Cristina Duran has for the last three years led a digital transformation programme in R&D at AstraZeneca. She has worked at the company for +10 years, holding leadership positions across global commercial, in country commercial and R&D. Prior to joining AstraZeneca, Cristina worked as a senior management consultant in Accenture. Cristina is passionate about innovation and enterprise value through change for the future.
Cristina Durán

Chief Digital Health Officer R&D, AstraZeneca

Digital participation